Liver Transplant in young adults with chronic hepatitis C virus: An argument for hepatitis C treatment in childhood

Experimental and Clinical Transplantation

Volumn 14, Issue 2, 2016, Pages 201-206

  Mohamad, Bashar ^a   Hanouneh, Ibrahim A ^a   Zein, Nizar N ^a   Lopez, Rocio ^a   Matloob, Ammar ^a   Alkhouri, Naim ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

End stage liver disease; Graft; Outcomes; Pediatric patients; Viral hepatitis

Indexed keywords

BILIRUBIN; CREATINE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; ANTIVIRUS AGENT;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL EFFECTIVENESS; COLD ISCHEMIA; CREATININE BLOOD LEVEL; END STAGE LIVER DISEASE; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; RECURRENT INFECTION; RETRANSPLANTATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; ADOLESCENT; ADVERSE EFFECTS; AGE; CHILD; FACTUAL DATABASE; HEPATITIS C, CHRONIC; KAPLAN MEIER METHOD; MORTALITY; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REOPERATION; RISK FACTOR; TIME FACTOR; TRANSPLANTATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CHILD; DATABASES, FACTUAL; FEMALE; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84962731372     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2015.0092     Document Type: Article

References (17)

1. Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006; 10(4): 919-940.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8): 556-562.
3. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014; 160(5): 293-300. doi: 10. 7326/M13-1133.
4. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis. 2000; 181(2): 419-424.
5. Casiraghi MA, De Paschale M, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004; 39(1): 90-96.
6. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008; 47(3): 836-843. doi: 10. 1002/hep. 22094.
7. Bortolotti F, Verucchi G, Camma C, et al; and the Italian Observatory for HCV Infection and Hepatitis C in Children. Longterm course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008; 134(7): 1900-1907. doi: 10. 1053/j. gastro. 2008. 02. 082.
8. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 suppl): S45-S57. doi: 10. 1016/j. jhep. 2014. 07. 027.
9. Minola E, Prati D, Suter F, et al. Age at infection affects the longterm outcome of transfusion-associated chronic hepatitis C. Blood. 2002; 99(12): 4588-4591.
10. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015; 29(1): 19-34.
11. Mack CL, Gonzalez-Peralta RP, Gupta N, et al; and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012; 54(6): 838-855. doi: 10. 1097/MPG. 0b013e318258328d.
12. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996; 334(13): 815-820.
13. Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation. Transplantation. 1996; 61(5): 701-705.
14. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32(4): 673-684.
15. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology. 1999; 117(3): 619-625.
16. Barshes NR, Udell IW, Lee TC, et al. The natural history of hepatitis C virus in pediatric a liver transplant recipients. Liver Transpl. 2006; 12(7): 1119-1123.
17. Gupta M, Bahirwani R, Levine MH, et al. Outcomes in pediatric hepatitis C transplant recipients: analysis of the UNOS database. Pediatr Transplant. 2015; 19(2): 153-163. doi: 10. 1111/petr. 12408.